Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heat waves and dirty air worsen lung disease, study finds

NCT ID NCT07261774

Knowledge-focused Sponsor: Mersin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 96 adults with asthma or COPD in Mersin, Türkiye, to see how extreme heat waves and air pollution impact their lung health. Researchers measured lung function, airway inflammation, symptoms, and quality of life during normal weather and again during heat waves. The goal was to understand how these environmental factors worsen disease control and increase the risk of flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors and public health officials better protect people with asthma and COPD during heat waves and high pollution days.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply to other regions or climates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

96 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult patients (≥18 years) diagnosed with asthma according to the GINA 2024 guidelines or COPD according to the GOLD 2024 guidelines, who are in a stable phase for at least four weeks. Participants must provide written informed consent and reside within the central district of Mersin. Patients with other chronic lung diseases, history of lung surgery, recent respiratory infections, active tuberculosis, significant comorbidities affecting lung function, pregnancy, active smoking within the past year, cancer history within the past five years, or those living outside Mersin city center will be excluded.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Provision of written informed consent For the asthma group: \- Diagnosis of asthma for at least 6 months according to the GINA 2024 guidelines Variable respiratory symptoms together with documented variable expiratory airflow limitation, demonstrated by at least one of the following: * Positive bronchodilator reversibility test (\>12% and \>200 mL increase in FEV1 10-15 minutes after 400 μg salbutamol) * Peak expiratory flow (PEF) variability (\>10% average daily PEF variability over 2 weeks) * Positive delayed reversibility (improvement in lung function after 4 weeks of anti-inflammatory treatment with \>12% and \>200 mL increase in FEV1 or \>20% increase in PEF) * Positive bronchial provocation test (≥20% fall in FEV1 with standard doses of methacholine or histamine) * Stable disease for at least 4 weeks prior to enrollment For the COPD group: * Diagnosis of COPD for at least 6 months according to the GOLD 2024 guidelines (post-bronchodilator FEV1/FVC \<70% in the presence of compatible clinical findings) * Stable disease for at least 4 weeks prior to enrollment Exclusion Criteria: * Presence of other pulmonary diseases apart from asthma or COPD (e.g., interstitial lung diseases, pleural diseases, pulmonary vascular diseases) * Pregnant women * History of cancer within the past 5 years * Previous lung surgery * Active pulmonary tuberculosis * Respiratory tract infection within the last 4 weeks * Presence of significant extrapulmonary disease that may affect lung function (e.g., cerebrovascular disease, acute myocardial infarction) * Active smoking within the past year * Residence outside the central district of Mersin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma chronic obstructive pulmonary disease COPD, severe early onset disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma (diagnosis) COPD (chronic obstructive pulmonary disease)

Contacts and locations

Locations

  • Mersin University Faculty of Medicin

    Mersin, Mersin, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.